ClinicalTrials.gg
Active, not recruitingNCT03837483Updated Sep 29, 2025

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

A Phase 3 interventional study of OTL-103 in Wiskott-Aldrich Syndrome, sponsored by Fondazione Telethon. Active, not recruiting at 2 sites in 2 countries. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Fondazione Telethon · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
Up to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Wiskott-Aldrich Syndrome with a site in United States — 3 open to participants now, 6 under way, 1 of them phase 3. Wiskott-Aldrich Syndrome · United States.

Enrollment
15th of 21
10 · median 24
Started
2019
the only one that year
Phase 3
3 of 29
none open now
Registered
27th of 29
by date
Lead sponsor
1 of 29
Fondazione Telethon

Among the 29 studies in Wiskott-Aldrich Syndrome with a site in United States, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 3, and was the 27th registered.

Wiskott-Aldrich Syndrome

41 studies on the registry are indexed under Wiskott-Aldrich Syndrome; 4 are open to participants now.

Browse Wiskott-Aldrich Syndrome studies →

Open to participants now

3 of the 29 studies in Wiskott-Aldrich Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Wiskott-Aldrich Syndrome studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: Up to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Wiskott-Aldrich Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation lentiviral vector.

03

Conditions studied

  • Wiskott-Aldrich Syndrome
04

Who can participate

Ages eligible
Up to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: up to 65 years
  • Diagnosis of WAS defined by genetic mutation and at least one of the following criteria:

    • Severe Wiskott-Aldrich Syndrome (WAS) gene mutation, defined by literature data (genotype/phenotype studies).;
    • Absent WASP expression, assessed by flow cytometry;
    • Severe clinical score (Zhu clinical score ≥ 3);
  • No human leukocyte antigen (HLA)-identical related donor available for hematopoietic stem cells transplant ().

Exclusion criteria

Exclusion Criteria:

  • End-organ dysfunction, severe active infection not responsive to treatment or other severe disease or clinical condition which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  • Malignant neoplasia (except local skin cancer) or a documented history of hereditary cancer syndrome.
  • Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and acute myeloid leukaemia , or other serious haematological disorders
  • Documented (HIV) infection
  • Prior hematopoietic stem cell transplantation, with evidence of residual cells of donor origin
  • Symptomatic herpes zoster, not responsive to specific treatment
  • Evidence of acute tuberculosis
  • Acute or chronic stable
  • Presence of positive RNA test result at screening
  • Patients not eligible for mobilization protocols in order to obtain CD34+ cells
  • Previous Gene Therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Gene Therapy

    OTL-103, Autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human WAS gene

    Genetic: OTL-103

Interventions

  • GeneticOTL-103

    Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA

06

What researchers measure

Primary outcomes

  1. Annualized rate of severe infections from 6 to 18 months after gene therapy compared with 1 year before gene therapy

    Time frame: 18 months

  2. Annualized rate of moderate and severe bleeding episodes up to 1 year after gene therapy compared with 1 year before gene therapy

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of the overall survival

    Time frame: 36 months

  2. Number of patients with Vector copy number (VCN)/cell > 0.1 measured in peripheral blood-derived CD3+ cells

    Time frame: 2 years

  3. Percentage of WAS protein expression increased from pre-treatment levels in lymphocytes

    Time frame: 2 years

  4. Percentage of WAS protein expression increased from pre-treatment levels in platelets

    Time frame: 2 years

  5. Number of participants with successful engraftment of OTL-103

    Engraftment of of OTL-103 is measured by hematological reconstitution of an absolute neutrophil count \> 500 cell/ul

    Time frame: 6 months

  6. The number of subjects presenting with malignancies or abnormal clonal proliferation

    Time frame: 2 years

07

Study locations

2 sites
  • Children's Healthcare of Atlanta, Inc
    Atlanta, Georgia 30329, United States
  • Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)
    Milan, 20132, Italy
08

References and documents

Publications

  • Quaranta P, Basso-Ricci L, Jofra Hernandez R, Pacini G, Naldini MM, Barcella M, Seffin L, Pais G, Spinozzi G, Benedicenti F, Pietrasanta C, Cheong JG, Ronchi A, Pugni L, Dionisio F, Monti I, Giannelli S, Darin S, Fraschetta F, Barera G, Ferrua F, Calbi V, Ometti M, Di Micco R, Mosca F, Josefowicz SZ, Montini E, Calabria A, Bernardo ME, Cicalese MP, Gentner B, Merelli I, Aiuti A, Scala S. Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasis. Blood. 2024 May 9;143(19):1937-1952. doi: 10.1182/blood.2023022666. PubMed 38446574 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Mar 2024, 61 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2019
First posted
Feb 12, 2019
StartActual
Jan 21, 2019
Primary completionActual
Mar 18, 2024
CompletionEst.
Sep 2027
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03837483
Lead sponsor
Fondazione Telethon
Collaborators
Ospedale San Raffaele
Responsible party
Sponsor
First posted
Feb 12, 2019
Start date
Jan 21, 2019
Primary completion
Mar 18, 2024
Completion
Sep 2027 (estimated)
Last update
Sep 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion